Related Experiment Video

Updated: Apr 26, 2026

Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy
08:34

Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy

Published on: September 25, 2017

24.1K

[Analysis of the effect of antihypertensive drugs on left ventricular hypertrophy regression]

N A Koziolova, I M Shatunova

    Kardiologiia
    |August 9, 2014
    PubMed

    Insights

    Combined treatment with renin-angiotensin-aldosterone system blockers and dihydropyridine calcium antagonists effectively reduces left ventricular mass. Fixed combinations offer advantages for hypertensive patients, improving adherence and reducing side effects.

    Area of Science:

    • Cardiovascular Medicine
    • Pharmacology

    Context:

    • Hypertension management is crucial for preventing cardiovascular complications.
    • Left ventricular mass is a key indicator of cardiovascular risk.
    • Renin-angiotensin-aldosterone system (RAAS) blockers and dihydropyridine calcium antagonists are cornerstone antihypertensive therapies.

    Purpose:

    • To review the leading role of combined RAAS blockers and dihydropyridine calcium antagonists in reducing left ventricular mass.
    • To highlight the benefits of fixed-dose combinations in hypertensive patients with left ventricular hypertrophy.
    • To discuss the advantages of angiotensin II receptor antagonists regarding side effect profile and patient adherence.

    Summary:

    • Combined therapy with RAAS blockers and dihydropyridine calcium antagonists demonstrates a leading role in reducing left ventricular mass.
    • Fixed combinations offer therapeutic advantages for hypertensive patients, particularly those with left ventricular hypertrophy.
    • Angiotensin II receptor antagonists present a favorable safety profile and high patient adherence compared to other antihypertensive classes, influencing initial therapy selection.

    Impact:

    • This review underscores the importance of combination therapy in managing hypertension and reducing cardiac remodeling.
    • Optimizing antihypertensive strategies with fixed combinations and favorable drug profiles can improve patient outcomes.
    • Evidence supports the use of specific drug classes and combinations for effective hypertension control and left ventricular mass reduction.

    More Related Videos

    Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents07:26

    Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents

    Published on: July 14, 2021

    4.6K
    Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR07:24

    Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

    Published on: April 8, 2013

    24.8K

    Related Concept Videos

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

    The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
    1.7K
    Heart Failure Drugs: Diuretics01:22

    Heart Failure Drugs: Diuretics

    Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
    1.4K
    Heart Failure Drugs: β-Blockers01:22

    Heart Failure Drugs: β-Blockers

    β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
    2.5K
    Heart Failure V: Medical Management01:30

    Heart Failure V: Medical Management

    Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
    617
    Heart Failure II: Pathophysiology01:29

    Heart Failure II: Pathophysiology

    Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
    1.7K
    Aortic Regurgitation III: Medical Management01:25

    Aortic Regurgitation III: Medical Management

    Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
    582